Drug
Exemestane clinical trials
Also written Aromasin, FCE-24304 and PNU 155971.
- studies test it
- 119
- open now
- 14
- in phase 3
- 36
- first study started
- 1996
Keep track of what changes. Save the exemestane studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Aromasin
- 38
Development codes
Studies by the year they started
116 studies that test it; most in 2017 (9)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1998 | 2 |
| 2000 | 1 |
| 2001 | 8 |
| 2002 | 6 |
| 2003 | 6 |
| 2004 | 6 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 9 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 58
- Phase 3
- 36
- Phase 4
- 7
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 41 · Other 78
Pfizer (13) · Novartis Pharmaceuticals (6) · National Cancer Institute (NCI) (3) · ETOP IBCSG Partners Foundation (3) · Institut Claudius Regaud (3) · NCIC Clinical Trials Group (3) · Roxane Laboratories (3) · Spanish Breast Cancer Research Group (2)
Often tested with
Tested in the same studies.
Tamoxifen (25) · Letrozole (20) · Anastrozole (19) · Fulvestrant (14) · Everolimus (13) · Palbociclib (5) · Abemaciclib (4) · Triptorelin (4)
Studies
Open first, then newest update. How each study uses exemestane is read from its arms, and is right about nine times in ten.
Testing it · 119
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationPhase 3Tolmar Inc.NCT05645536Written as Exemestane Tablets
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingPhase 3PfizerNCT07062965Written as Exemestane
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06979596Written as Exemestane
- E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen StudyRecruitingPhase 1University of North Carolina, Chapel HillNCT07706374Written as Exemestane 25 MG
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingPhase 3Stemline Therapeutics, Inc.NCT06492616Written as Exemestane
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Exemestane
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786Written as Exemestane
- Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingPhase 2European Institute of OncologyNCT07395336Written as elacestrant and exemestane
- Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07499999Written as Exemestane
- Sapu003 in Advanced mTOR-sensitive Solid TumorsRecruitingPhase 1SAPU NANO (US) LLCNCT07369505Written as Exemestane 25 MG
- Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.RecruitingPhase 2Andrea DeCensiNCT06364267Written as Exemestane 25 MG
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingPhase 1Hunan Cancer HospitalNCT07163481Written as Sacituzumab Govitecan + Anastrozole / Exemestane
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingPhase 3Region Örebro CountyNCT06223698Written as Exemestane
- Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingPhase 2Guangdong Provincial People's HospitalNCT04858516Written as palbociclib and exemestane plus trastuzumab and pyrotinib
- ER Reactivation Therapy for Breast CancerCompletedPhase 2Dartmouth-Hitchcock Medical CenterNCT02188745Written as Exemestane
- Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast CancerCompletedPhase 2Irada Ibrahim-zadaNCT05150652Written as Exemestane 25 mg
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerCompletedPhase 3ETOP IBCSG Partners FoundationNCT00066690Written as Exemestane
- Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT06169124Written as Exemestane
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT04975308Written as Exemestane
- A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedPhase 2OHSU Knight Cancer InstituteNCT06630325Written as Exemestane
See all 119 studies that test exemestane →
Given in every arm · 70 — exemestane is usual care beside what is tested
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruitingPhase 3National Cancer Institute (NCI)NCT07391774Written as Exemestane
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336Written as Exemestane
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303Written as Exemestane
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingPhase 2Oana DanciuNCT05467891Written as Exemestane
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Written as Exemestane
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Written as Exemestane
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingPhase 2Fujian Cancer HospitalNCT07581834Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingPhase 3Fudan UniversityNCT05891093Written as Exemestane
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingPhase 3SWOG Cancer Research NetworkNCT01674140Written as exemestane
- Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05827081Written as Exemestane
- Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerActive, not recruitingPhase 3Tolmar Inc.NCT04906395Written as Exemestane Tablets
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02115282Written as Exemestane
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingPhase 3Alliance Foundation Trials, LLC.NCT02947685Written as Exemestane
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01272037Written as Exemestane
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast CancerCompletedPhase 2Mayo ClinicNCT03179904Written as Exemestane
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Active, not recruitingPhase 3National Cancer Institute (NCI)NCT00310180Written as Exemestane
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedPhase 1Eisai Co., Ltd.NCT04572295Written as Exemestane
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT06001762Written as Exemestane
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingPhase 1Eli Lilly and CompanyNCT02057133Written as Exemestane
- Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedPhase 2PfizerNCT02007512Written as exemestane
Showing 20 of 70.
As the comparator · 29 — what is tested is compared with exemestane
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951Written as Exemestane
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364Written as Exemestane 25 MG
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173Written as Exemestane tablets
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953Written as Exemestane
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05472792Written as tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07349069Written as Exemestane tablets
- Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)RecruitingPhase 3Japanese Foundation for Cancer ResearchNCT07190443Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingPhase 2Royal Marsden NHS Foundation TrustNCT04985266Written as Exemestane
- Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialSuspendedPhase 3Alliance for Clinical Trials in OncologyNCT06671912Written as Exemestane
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06428396Written as Exemestane
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingPhase 2PfizerNCT06105632Written as Exemestane
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingPhase 3Olema Pharmaceuticals, Inc.NCT06016738Written as Exemestane
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06680921Written as Exemestane tablets
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingPhase 3AstraZenecaNCT05952557Written as Exemestane
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340Written as Exemestane
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05514054Written as Exemestane
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerTerminatedPhase 2SanofiNCT04059484Written as Exemestane
- ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast CancerActive, not recruitingPhase 3Azienda Ospedaliero-Universitaria CareggiNCT04134598Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerTerminatedPhase 3Veru Inc.NCT04869943Written as Exemestane
- Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast CancerWithdrawnPhase 2Veru Inc.NCT05079360Written as Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Showing 20 of 29.
Codes
What other systems call exemestane · ClinicalTrials.gg INT003387
- MeSH (NLM) C056516exemestaneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) NY22HMQ4BXEXEMESTANEConfirmed FDA, NLM, Wikidata
- RxNorm 258494Confirmed FDA, Wikidata
- Wikidata Q418819exemestaneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1097ExemestaneOne source FDA
- DrugBank DB00990One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C056516 | exemestane | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | NY22HMQ4BX | EXEMESTANE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 258494 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418819 | exemestane | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1097 | Exemestane | One source FDA |
| DrugBank | DB00990 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.